Sign Up
Stories
Gritstone bio Delays COVID-19 Vaccine Trial
Share
AI-Powered Antigen Research Partnership
Advancements in Antibodies to Protect Im...
BioNTech's mRNA Cancer Vaccine Progress
Antibody Therapeutics Market Surge
China's Bio Reagent Market Growth
Cue Biopharma to Present Corporate Updat...
Overview
API
Gritstone bio delays Phase 2b COVID-19 vaccine trial to 1H 2024 to use fully GMP-grade raw materials, supported by federal funds.
Ask a question
How might the delay in the Phase 2b trial impact the timeline for the COVID-19 vaccine's availability?
In what ways could the focus on developing potent vaccines using innovative vectors affect the effectiveness of future vaccines?
What are the potential implications of using fully GMP-grade raw materials in vaccine production?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Nov 2023
Dec 2023
Jan 2024
Coverage